CRC Research Update — August 15, 2026
Today's colorectal cancer research highlights
metastatic
A collection of 122 issues
Trifluridine/tipiracil outcomes examined in patients 75 and older
Skip to content
The CRC Digest
▸ TREATMENT
Trifluridine/tipiracil outcomes examined in patients 75 and older
A single-center retrospective study compared relative dose intensity, toxicity, and survival between trifluridine/tipiracil (FTD/TPI) monotherapy and FTD/TPI plus bevacizumab in older patients with metastatic colorectal cancer, examining the relationship between dose
CRC Research Update — August 14, 2026
Today's colorectal cancer research highlights
Sotorasib Plus Panitumumab Compared to Standard Therapy in Chemorefractory Metastatic CRC
Skip to content
The CRC Digest
▸ TREATMENT
Sotorasib Plus Panitumumab Compared to Standard Therapy in Chemorefractory Metastatic CRC
A matching-adjusted indirect comparison evaluated sotorasib plus panitumumab versus trifluridine/tipiracil plus bevacizumab in chemorefractory metastatic colorectal cancer. (Clinical Colorectal Cancer)
This content is informational only and does not constitute medical advice.
KRAS Mutations and Liver Metastases Predict Worse Outcomes in Third-Line Metastatic CRC
Skip to content
The CRC Digest
◇ RESEARCH
KRAS Mutations and Liver Metastases Predict Worse Outcomes in Third-Line Metastatic CRC
A pooled analysis of placebo-controlled trials from the ARCAD CRC Database found that KRAS mutations and liver metastases are independently associated with poorer prognosis in patients receiving third-line therapy for metastatic
CRC Research Update — August 13, 2026
Today's colorectal cancer research highlights
Dual immunotherapy may outperform single-agent pembrolizumab in MSI-H metastatic colorectal cancer
Skip to content
The CRC Digest
◆ TRIAL DATA
Dual immunotherapy may outperform single-agent pembrolizumab in MSI-H metastatic colorectal cancer
An indirect comparison using reconstructed patient data from KEYNOTE-177 and CheckMate 8HW suggests nivolumab-ipilimumab may offer progression-free survival benefits over pembrolizumab in first-line MSI-H/dMMR metastatic disease, though grade 3/4
CRC Research Update — August 11, 2026
Today's colorectal cancer research highlights
Economic evaluation compares nivolumab plus ipilimumab versus nivolumab alone in dMMR/MSI-H metastatic CRC
Skip to content
The CRC Digest
Economic evaluation compares nivolumab plus ipilimumab versus nivolumab alone in dMMR/MSI-H metastatic CRC
A Chinese study used a three-state partitioned survival model to evaluate nivolumab plus ipilimumab versus nivolumab monotherapy in previously treated metastatic colorectal cancer patients with dMMR/MSI-H, using Kaplan-Meier curves
Case report shows successful re-challenge with encorafenib, cetuximab, and nivolumab in BRAF V600E cancer
Skip to content
The CRC Digest
▸ TREATMENT
Case report shows successful re-challenge with encorafenib, cetuximab, and nivolumab in BRAF V600E cancer
A patient with BRAF V600E mutated, mismatch-repair-proficient metastatic colorectal cancer responded to re-challenge with encorafenib and cetuximab combined with nivolumab after prior progression, suggesting this combination may offer renewed